Name | Value |
---|---|
Revenues | 0.0M |
Cost of Revenue | 0.6M |
Gross Profit | -0.6M |
Operating Expense | 26.5M |
Operating I/L | -26.5M |
Other Income/Expense | 2.0M |
Interest Income | 2.0M |
Pretax | -24.6M |
Income Tax Expense | -2.0M |
Net Income/Loss | -22.6M |
Icosavax, Inc. is a biopharmaceutical company specializing in the development of vaccines for life-threatening respiratory diseases using its virus-like particle (VLP) platform technology. The company's pipeline includes IVX-121, a vaccine candidate targeting RSV under Phase 1/1b clinical trial; IVX-A12, a RSV/hMPV bivalent antigen candidate; IVX-241, targeting hMPV; and IVX-411, an original RBD sequence antigen with SARS-CoV-2 target under Phase 1/2 clinical trial.